bml-111

BML-111 is a synthetic analog of lipoxin A4 and acts as an agonist for the lipoxin A4 receptor (ALX/FPR2). It exhibits potent anti-inflammatory and pro-resolving properties by modulating multiple signaling pathways. BML-111 has been shown to repress angiotensin converting enzyme (ACE) activity while increasing ACE2 activity, thereby regulating the renin-angiotensin-aldosterone system (RAAS). It reduces inflammation and oxidative stress in various injury models, including acute lung/liver injury, spinal cord injury, neuroinflammation following sepsis, and UVB-induced skin inflammation. Additionally, BML-111 inhibits epithelial-mesenchymal transition (EMT) and migration in cancer cells by downregulating MMPs via the 5-lipoxygenase pathway. The drug is considered for potential therapeutic use in inflammatory diseases and certain cancers[2][6][7].

Other names

5(S)-6(R)-7-trihydroxyheptanoic-acid-methyl-esterLipoxin A4 receptor agonistFPR2 agonistFPR-2 agonistFPR 2 agonistALX/FPR2 receptor agonist